Article

Start-up Alimera Sciences receives funding for ophthalmic products

Series A financing worth $26.75 million will be used by Alimera Sciences Inc. for acquisition and continued development of the company's ophthalmic pharmaceutical pipeline, along with commercialization of the company's over-the-counter ophthalmic products.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200
March 20th 2025

Ocugen to move forward with dosing of second cohort of phase 1 clinical trial of OCU200

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Stem cell-based CALEC therapy achieves 90% corneal surface restoration in clinical trial
March 20th 2025

Stem cell-based CALEC therapy achieves 90% corneal surface restoration in clinical trial

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

OSRX expands medication sizes and adds direct-to-patient post-op kits
March 19th 2025

OSRX expands medication sizes and adds direct-to-patient post-op kits

Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
March 19th 2025

Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes

© 2025 MJH Life Sciences

All rights reserved.